Predictors of Extent of Abnormal Myocardial Perfusion (SSS) in Patients Without Obstructive Epicardial CAD
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Predictor | Exp β (95% CI) | P | Exp β (95% CI) | P |
| FMD (%) | 0.61 (0.48–0.78) | <0.001 | 0.58 (0.43–0.75) | <0.001 |
| CAC score | 1.00 (0.99–1.00) | 0.22 | — | — |
| Age (y) | 1.01 (0.98–1.06) | 0.45 | — | — |
| Male sex | 1.57 (0.66–3.75) | 0.31 | — | — |
| Diabetes mellitus duration (y) | 0.98 (0.95–1.01) | 0.33 | — | — |
| Body mass index (kg/m2) | 1.02 (0.95–1.09) | 0.59 | — | — |
| Hemoglobin A1c (mmol/L) | 0.76 (0.55–1.04) | 0.09 | 0.50 (0.31–0.82) | 0.01 |
| Smoking | 0.91 (0.33–2.53) | 0.86 | — | — |
| Family history of CAD | 0.93 (0.39–2.21) | 0.86 | 0.36 (0.11–1.19) | 0.09 |
| Hypercholesterolemia | 1.65 (0.64–4.29) | 0.30 | 4.04 (1.07–15.24) | 0.04 |
| Hypertension | 1.22 (0.51–2.90) | 0.66 | — | — |
| Type 1 diabetes mellitus | 0.16 (−0.90–1.22) | 0.77 | — | — |
| Treatment with only diet | 1.57 (−0.78–3.91) | 0.19 | — | — |
| Treatment with oral agents | −0.41 (−1.51–0.68) | 0.45 | — | — |
| Treatment with insulin | 0.15 (−1.18–1.47) | 0.83 | — | — |
| Statin use | 0.36 (−0.71–1.43) | 0.50 | — | — |
| Aspirin use | 0.79 (−0.70–2.27) | 0.30 | — | — |
| Angiotensin-converting enzyme inhibitor use | −0.14 (−1.59–1.31) | 0.85 | — | — |
| β-blocker use | 0.15 (−1.76–2.05) | 0.88 | — | — |
| Angiotensin II antagonist use | −0.99 (−2.57–0.58) | 0.21 | — | — |
| Calcium channel blocker use | 0.95 (−1.06–2.97) | 0.35 | — | — |
| Diureticum use | 0.16 (−1.52–1.85) | 0.85 | — | — |
CI = confidence interval; β = β-coefficient.